Shaakir Hasan

Shaakir Hasan

Auto-generated profile, based on publicly available information

Shaakir Hasan

New York Proton Center, New York, NY 10035, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Annals of Surgery
Verified
Journal Article
Closed access
SHShaakir Do Hasan
Shaakir Do Hasan
PRPaul Do Renz
Paul Do Renz
RWRodney E. Wegner
Rodney E. Wegner
GFGene Finley
Gene Finley
MRMoses Raj
Moses Raj
AKAlexander Kirichenko
Alexander Kirichenko
Objective: The relationship between microsatellite instability (MSI) and response to neoadjuvant chemoradiation in rectal cancer is not well understood. Background: We utilized the National Cancer Database (NCDB) to investigate the association between MSI and pathologic complete response (pCR) in this patient population. Methods: We analyzed 5086 patients between 2010 and 2015 with locally advanced rectal cancer who were tested for MSI and treated definitively with chemoradiation followed by surgery. Primary comparison groups were between 4450 MSI-negative(−) and 636 MSI-positive(+) patients. Multivariable regression analysis was conducted to identify demographic, therapeutic, and clinical characteristics predictive of pCR. Cox proportional-hazard ratios were used for survival. Results: All patients were treated with definitive chemoradiation (median dose 50.4 Gy) followed by resection within 4 months. MSI(+) patients were associated with earlier year of diagnosis and higher-grade tumors (P < 0.05). The overall pCR rate was 8.6%, including 8.9% for MSI(−) and 5.9% for MSI(+) tumors (P = 0.01). Along with lower T stage, MSI(+) cases were significantly associated with a reduced pCR rate (odds ratio 0.65, 95% confidence interval 0.43–0.96) with multivariable analysis. The 5-year survival for patients with pCR was 93% compared with 73% without it (<0.001). Conclusion: Microsatellite instability was independently associated with a reduction in pCR for locally advanced rectal cancer after neoadjuvant chemoradiation in this NCDB-based analysis.

1 September 2018 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
PRPaul Renz
Paul Renz
SHShaakir Hasan
Shaakir Hasan
SGSteven Gresswell
Steven Gresswell
RHRaymond T. Hajjar
Raymond T. Hajjar
MTMark Trombetta
Mark Trombetta
JFJames Fontanesi
James Fontanesi

1 October 2019 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Closed access
PDF file
SHShaakir Hasan
Shaakir Hasan
SAStephen Abel
Stephen Abel
VVVivek Verma
Vivek Verma
PWPatrick Webster
Patrick Webster
WAW. Tristam Arscott
W. Tristam Arscott
CSCharles Simone
Charles Simone
Background: Stereotactic body radiation therapy (SBRT) and proton beam therapy (PBT) generally are safe and effective for non-operative hepatocellular carcinoma (HCC). To date, data comparing the two modalities are limited. We aimed to identify the practice patterns and outcomes of nonsurgical HCC cases treated definitively with either SBRT or PBT. Methods: We queried the National Cancer Database for T1–2N0 HCC patients receiving PBT or SBRT from 2004 to 2015. Patients were excluded for any treatment other than non-palliative external beam radiotherapy. A multivariable binomial regression model identified patterns of SBRT/PBT use, and propensity-matched multivariable Cox regression assessed correlates of survival. Results: A total of 71 patients received PBT and 918 patients received SBRT (median follow-up 45 months). SBRT was used in 1.8% of nonoperative early stage HCC cases in 2004 and 4.2% of cases in 2015, whereas PBT was used in 0.1–0.2% of cases every year. The median biologically effective dose (BED) for SBRT and PBT was 100 Gy10 and 98 Gy10, respectively (OR =0.70, P=0.17). Factors predictive of receiving PBT included: white race, higher comorbidity score, higher education, metropolitan residence, tumors >5 cm and recent treatment (all P<0.05). Both PBT (HR =0.48, 95% CI: 0.29–0.78) and BED ≥100 Gy10 (HR =0.61, 95% CI: 0.38–0.98) were independent predictors for longer survival. Conclusions: Although not implying causation and requiring prospective corroboration, PBT was independently associated with longer survival than SBRT, despite being delivered to HCC patients with multiple poor prognostic factors. PBT may also allow for safer BED escalation, which also independently associated with outcomes.

8 June 2022 in Cancer Medicine
Verified
Journal Article
Open access
SHShaakir Hasan
Shaakir Hasan
SLStanislav Lazarev
Stanislav Lazarev
MGMadhur Garg
Madhur Garg
KMKeyur Mehta
Keyur Mehta
RPRobert H. Press
Robert H. Press
DGDaniel Gorovets
Daniel Gorovets
Background: We investigate the impact of gender, race, and socioeconomic status on the diagnosis and management of bladder cancer in the United States.Methods: We utilized the National Cancer Database to stratify cases of urothelial cell carcinoma of the bladder as early (Tis, Ta, T1), muscle invasive (T2–T3, N0), locally advanced (T4, N1–3), and metastatic. Multivariate binomial and multinomial logistic regression analyses identified demographic characteristics associated with stage at diagnosis and receipt of cancer‐directed therapies. Odds ratios (OR) are reported with 95% confidence intervals.Results: After exclusions, we identified 331,714 early, 72,154 muscle invasive, 15,579 locally advanced, and 15,161 metastatic cases from 2004–2016. Relative to diagnosis at early stage, the strongest independent predictors of diagnosis at muscle invasive, locally advanced, and metastatic disease included Black race (OR = 1.19 [1.15–1.23], OR = 1.49 [1.40–1.59], OR = 1.66 [1.56–1.76], respectively), female gender (OR = 1.21 [1.18–1.21], OR = 1.16 [1.12–1.20], and OR = 1.34 [1.29–1.38], respectively), and uninsured status (OR = 1.22 [1.15–1.29], OR = 2.09 [1.94–2.25], OR = 2.57 [2.39–2.75], respectively). Additional demographic factors associated with delayed diagnosis included older age, treatment at an academic center, Medicaid insurance and patients from lower income/less educated/more rural areas (all p < 0.01).Treatment at a non‐academic center, older age, women, Hispanic and Black patients, lower income and rural areas were all less likely to receive cancer‐directed therapies in early stage disease (all p < 0.01). Women, older patients, and Black patients remained less likely to receive treatment in muscle invasive, locally advanced, and metastatic disease (all p < 0.01).Conclusion: Black race was the strongest independent predictor of delayed diagnosis and substandard treatment of bladder cancer.

28 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MPMichael Pennock
Michael Pennock
AWAlex Wei
Alex Wei
CCChingyun Cheng
Chingyun Cheng
HLHaibo Lin
Haibo Lin
SHShaakir Hasan
Shaakir Hasan
RPRobert H. Press
Robert H. Press
Proton pencil-beam scanning (PBS) Bragg peak FLASH combines ultra-high dose rate delivery and organ-at-risk (OAR) sparing. This proof-of-principle study compared dosimetry and dose rate coverage between PBS Bragg peak FLASH and PBS transmission FLASH in head and neck reirradiation. PBS Bragg peak FLASH plans were created via the highest beam single energy, range shifter, and range compensator, and were compared to PBS transmission FLASH plans for 6 GyE/fraction and 10 GyE/fraction in eight recurrent head and neck patients originally treated with quad shot reirradiation (14.8/3.7 CGE). The 6 GyE/fraction and 10 GyE/fraction plans were also created using conventional-rate intensity-modulated proton therapy techniques. PBS Bragg peak FLASH, PBS transmission FLASH, and conventional plans were compared for OAR sparing, FLASH dose rate coverage, and target coverage. All FLASH OAR V40 Gy/s dose rate coverage was 90–100% at 6 GyE and 10 GyE for both FLASH modalities. PBS Bragg peak FLASH generated dose volume histograms (DVHs) like those of conventional therapy and demonstrated improved OAR dose sparing over PBS transmission FLASH. All the modalities had similar CTV coverage. PBS Bragg peak FLASH can deliver conformal, ultra-high dose rate FLASH with a two-millisecond delivery of the minimum MU per spot. PBS Bragg peak FLASH demonstrated similar dose rate coverage to PBS transmission FLASH with improved OAR dose-sparing, which was more pronounced in the 10 GyE/fraction than in the 6 GyE/fraction. This feasibility study generates hypotheses for the benefits of FLASH in head and neck reirradiation and developing biological models.

1 February 2019 in Lung Cancer
Verified
Journal Article
Closed access
SAStephen Abel
Stephen Abel
SHShaakir Hasan
Shaakir Hasan
RWRichard White
Richard White
LSLana Schumacher
Lana Schumacher
GFGene Finley
Gene Finley
RWRodney E. Wegner
Rodney E. Wegner